Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra 11:35:09 2024-05-15 am EDT After market 03:59:27 pm
165.8 EUR +4.77% Intraday chart for Merck KGaA 164.6 -0.77%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
EU GDP Estimates, Rosy Spring Forecast Prop Up German Stocks MT
MERCK : Electronics came as a big surprise Alphavalue
UBS rates Merck KGaA a 'Buy' - Target 186 euros DP
MERCK KGAA : UBS maintains a Buy rating ZD
Positive quarterly report pushes Merck KGaA to annual high DP
Merck KGaA: 13% decline in quarterly adjusted EPS CF
Industrials lift European shares to record high ahead of US inflation data RE
Merck KGaA Posts Lower Q1 Attributable Profit, Net Sales MT
Merck KGaA's Q1 adjusted profit declines less than feared RE
Merck KGaA Confirms Outlook After Drop in Sales, Earnings DJ
Cinven to explore $3 billion sale of software maker Jaggaer, sources say RE
MERCK KGAA : UBS reiterates its Buy rating ZD
MERCK KGAA : Gets a Buy rating from JP Morgan ZD
MERCK KGAA : Receives a Buy rating from Deutsche Bank ZD
Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region MT
MERCK KGAA : Gets a Buy rating from UBS ZD
Biocartis Announces Expansion of Its Collaboration with Merck Serono Middle East and North Africa CI
MERCK KGAA : JP Morgan maintains a Buy rating ZD
MERCK KGAA : Jefferies keeps its Buy rating ZD
Habeck's 'pharma trip' - industry sees structural problems DP
Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board DP
Transcript : Merck KGaA - Shareholder/Analyst Call
Scholz pledges further support for the pharmaceutical industry DP
Scholz promises support for pharma sector in Germany as Merck invests RE
Merck KGaA Starts Building EUR300 Million Life Science Research Center in Germany MT
Chart Merck KGaA
More charts
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
158.3 EUR
Average target price
180.1 EUR
Spread / Average Target
+13.79%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck KGaA
  5. Merck: 2024 weakness might impact the 2025 targets
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW